Pre-diagnostic circulating metabolomics and prostate cancer risk: A systematic review and meta-analysis.

ABSTRACT:

Background

Metabolomic dysregulation contributes to prostate cancer (PCa) pathogenesis, and studies suggest that circulating metabolites have strong clinical potential to act as biomarkers. However, evidence of circulating metabolite associations has not been quantitively aggregated.

Methods

Systematic searches were performed in PubMed and Embase (October 17^th, 2024) to identify pre-diagnostic untargeted serum metabolomic studies of PCa risk. After harmonizing metabolite names across studies, restricted maximum likelihood was used to conduct meta-analyses to quantify associations between metabolites and risk of overall PCa, low- to intermediate-risk PCa, high- to very high-risk PCa and lethal PCa, as defined by the NCCN. Statistical significance was defined as FDR

SUBMITTER: Fuller H 

PROVIDER: S-EPMC11888532 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature